

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) An RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases as defined by Seq. ID No. 10.
- 2-3. (canceled)
4. (previously presented) The RNA molecule of claim 1, wherein the RNA molecule consists of Seq. ID No. 10.
- 5- 9. (canceled)
10. (previously presented) A pharmaceutical composition comprising an RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases as defined by Seq. ID No. 10 , together with a pharmaceutically acceptable carrier.
11. (original) The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable carrier is a sterile injectable solution.

12-13. (canceled)

14. (previously presented) The pharmaceutical composition of claim 10, wherein the RNA molecule consists of Seq. ID No. 10.

15-19. (canceled).

20. (withdrawn) A method of treating a cancer that expresses clusterin, comprising administering to an individual in need of treatment an RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases as defined by Seq. ID No. 10.

21- 22 (canceled)

23. (withdrawn) The method of claim 22, wherein the RNA molecule consists of Seq. ID No. 10.

24- 28 (canceled)

29. (withdrawn) The method of claim 20, wherein the cancer is selected from the group consisting of sarcomas, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma.

30- 34. (canceled)

35. (new) The RNA molecule of claim 1, wherein the RNA molecule is a double stranded molecule, and one of the strands consists of Seq ID No. 10.

36. (new) The pharmaceutical composition of claim 10, wherein the RNA molecule is a double stranded molecule, and one of the strands consists of Seq ID No. 10.

37. (new, withdrawn) The method of claim 20, wherein the RNA molecule is a double stranded molecule, and one of the strands consists of Seq ID No. 10.